Fig. 7

ATRX mutation is associated with favorable clinical benefit to ICI. a Comparison of TMB between ATRX mutant and wild type ICI-treated patients in sub cohort of gastric cancer and the whole cohort. b Kaplan–Meier analysis of comparing overall survival between patients with or without ATRX mutation in sub cohort of gastric cancer and the whole cohort. c Correlation of ATRX mutation with overall survival benefits stratified by sex in the whole cohort. Female patients with ATRX mutation obtained significantly prolonged overall survival compared with wild type female patients. The HR of ATRX mutant type vs wild type for female patients (HR = 0.636, 95%CI = 0.455–0.890, P = 0.023) is better than the HR for male patients (HR = 0.929, 95%CI = 0.596–1.362, P = 0.7117)